Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format.
The company is not trading in connection with the Merck takeover
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Pandion Therapeutics news
01.04.2021
Merck has completed its acquisition of Pandion Therapeutics for $60 per share.
Source: 
merck.com
merck.com
25.02.2021
Merck & Co. is buying biotechnology company Pandion Therapeutics for $1.85 billion, or $60 per share. Pandion develops drugs for the treatment of autoimmune diseases. The deal is scheduled to close in the first half of 2021.
Source: merck.com
merck.com
01.09.2020
Loss of Pandion Therapeutics under GAAP in 6 months. In 2020, the loss was $15.657 million, up 36.3% from $11.49 million in the previous year. Revenue amounted to $3.956 million. During 6 months of 2019 the company did not receive any revenue.
Source: 
investors.pandiontx.com
investors.pandiontx.com
General information
| Company name | Pandion Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | /companies/PAND:US |
| Website | investors.pandiontx.com |
| Information disclosure | www.sec.gov |
English (US) 